Etrolizumab - CISMeF

Preferred Label : Etrolizumab;

NCIt synonyms : rhuMAb Beta7; Immunoglobulin G1, anti-(human integrin alpha4beta7/integrin alphaEbeta7) (human-rat monoclonal rhuMAb beta7 heavy chain), disulfide with human-rat monoclonal rhuMAb beta7 light chain, Dimer; Anti-Beta7;

NCIt definition : A humanized monoclonal antibody targeting the beta7 subunit of the heterodimeric integrins alpha4beta7 and alphaEbeta7, with anti-inflammatory activity. Etrolizumab binds to the beta subunit of the alpha4beta7 and alphaEbeta7 integrins in the gastronintestinal tract blocking their activity. This prevents integrin-mediated leukocyte migration to and accumulation in sites of inflammation.;

UNII : I2A72G2V3J;

CAS number : 1044758-60-2;

Molecule name : RG7413; PRO145223;

Details

Origin ID

C97944;

UMLS CUI

C3177463;

Automatic exact mappings (from CISMeF team)
- etrolizumab [MeSH concept]
- rhuMAb Beta7 [MeSH concept]
Currated CISMeF NLP mapping
- etrolizumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- etrolizumab [MeSH Supplementary Concept]
- rhuMAb Beta7 [MeSH concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients